Surrey Hills, Australia

Andrew Wei

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignees: Les Laboratoires Servier, Novartis Ag. Active years: 2022.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Andrew Wei

Introduction

Andrew Wei is a notable inventor based in Surrey Hills, Australia. He has made significant strides in the field of hematologic cancer treatment through his innovative research and development. His work focuses on combining a specific inhibitor with standard care treatments to enhance therapeutic outcomes for patients.

Latest Patents

Andrew Wei holds a patent for a groundbreaking invention titled "Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof." This patent describes a combination that includes a Mcl-1 inhibitor and a second anticancer agent, which can be selected from anthracyclines, cytarabine, and hypomethylating agents. The compositions and uses outlined in this patent aim to improve treatment efficacy for patients suffering from hematologic cancers. He has 1 patent to his name.

Career Highlights

Throughout his career, Andrew Wei has worked with prominent companies in the pharmaceutical industry, including Les Laboratoires Servier and Novartis AG. His experience in these organizations has contributed to his expertise in drug development and cancer research.

Collaborations

Andrew Wei has collaborated with esteemed colleagues in his field, including Donia Moujalled and Giovanna Pomilio. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to significant advancements in cancer treatment.

Conclusion

Andrew Wei's contributions to the field of hematologic cancer treatment through his innovative patent and collaborations with leading companies and professionals highlight his commitment to improving patient outcomes. His work continues to inspire advancements in cancer therapies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…